Zobrazeno 1 - 10
of 1 203
pro vyhledávání: '"G. Von Minckwitz"'
Publikováno v:
Diagnostic Pathology, Vol 1, Iss 8 (2016)
Introduction/ Background The measurement of cell proliferation via Ki67 immunohistochemistry is an important part of tumor diagnostics leading to treatment decisions. The assessment according to the current guidelines is very time consuming which lik
Externí odkaz:
https://doaj.org/article/1ac4518f1ea346dc937065f889242924
Autor:
Alison Conlin, Thomas Boulet, Georg Kunz, J.C. Alcedo, Andrea Fontana, Irene Wapnir, Norman Wolmark, Xavier Pivot, Max S. Mano, Adam Brufsky, S. Loibl, D. Tesarowski, Chunyan Song, Bella Kaufman, Youngsen Yang, Melanie Smitt, Mahasti Saghatchian, Martina Zimovjanova, Michael Untch, G. von Minckwitz, Jonathan Polikoff, Charles E. Geyer, S. Kuemmel, H. Liu, Eleftherios P. Mamounas, John Hackmann, Lisa H. Lam, C.-S. Huang, T. Kuehn, Michael P. DiGiovanna
Publikováno v:
Annals of Oncology. 32:1005-1014
Background In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a 50% reduction in risk of recu
Autor:
S. Loibl, M. Untch, N. Burchardi, J. Huober, B.V. Sinn, J.-U. Blohmer, E.-M. Grischke, J. Furlanetto, H. Tesch, C. Hanusch, K. Engels, M. Rezai, C. Jackisch, W.D. Schmitt, G. von Minckwitz, J. Thomalla, S. Kümmel, B. Rautenberg, P.A. Fasching, K. Weber, K. Rhiem, C. Denkert, A. Schneeweiss
Publikováno v:
Annals of Oncology. 33:743-744
Autor:
Jörg Thomalla, G. von Minckwitz, J Huober, EM Grischke, S. Loibl, Hans Tesch, C. Jackisch, Wolfgang D. Schmitt, PA Fasching, Knut Engels, Andreas Schneeweiss, Beate Rautenberg, Carsten Denkert, Karsten Weber, Michael Untch, J-U Blohmer, Nicole Burchardi, S Kümmel, Mahdi Rezai, Bruno Valentin Sinn, Claus Hanusch, Jenny Furlanetto, K Rhiem
Publikováno v:
Annals of Oncology. 30:1279-1288
Combining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC). Therefore, we evaluated the addition of durvalumab to standard neoadjuvant chemotherapy (NA
Autor:
Michael Untch, T Karn, Ahmed El-Balat, Andreas Schneeweiss, G. von Minckwitz, Sven Becker, U. Holtrich, Christos Hatzis, Achim Rody, Karsten Weber, Tobias Meissner, L Pusztai, C. Solbach, S. Loibl, Bruno Valentin Sinn, C Denkert, Valentina Nekljudova
Publikováno v:
Cancer Research. 79:P3-10
Background: We have previously shown that expression of the IL8/VEGFA-metagene eliminates the good prognostic effect of TILs in TNBC (PMID 21978456, 28750120). We also showed that the VEGFA metagene predicted response to neoadjuvant bevacizumab in th
Autor:
Keyur Mehta, Hans Tesch, Michael Untch, K Rhiem, J-U Blohmer, J Huober, C. Solbach, Andreas Schneeweiss, Mahdi Rezai, Christoph Salat, S. Loibl, PA Fasching, G. von Minckwitz, C. Jackisch, C Denkert, Valentina Nekljudova, Fenja Seither, Claus Hanusch
Publikováno v:
Cancer Research. 79:P2-08
Background Even though patients with a pCR following neoadjuvant chemotherapy have an excellent prognosis still some of these patients will eventually relapse. A better identification of pts with an increased risk of relapse despite a pCR would be he
Autor:
Andrew T. Chan, B. Barnett, H. Iwata, Noelia Martínez, T Fujita, A Murias Rosales, A Luczak, Marc Buyse, Fan Xu, Manuel Ruiz-Borrego, M. Gnant, M Spencer, Beverly Moy, F.A. Holmes, HS Rugo, Suzette Delaloge, Janine Mansi, Serafin Morales, M. Martin, Carlos Barrios, T Galeano, S.R.D. Johnston, C. Jackisch, Bent Ejlertsen, Cristina Saura, S Chia, Jo Chien, M Bhandari, G. von Minckwitz
Publikováno v:
Cancer Research. 79:P2-13
Background: The international, randomized, placebo-controlled phase III ExteNET trial showed that 1 year (yr) of neratinib 240 mg/day after trastuzumab-based adjuvant therapy significantly improved invasive disease-free survival (iDFS) in 2840 patien
Autor:
T Karn, C. Jackisch, Andreas Schneeweiss, Karsten Weber, Jörg Thomalla, H. P. Sinn, Frederick Klauschen, Bruno Valentin Sinn, Denise Treue, Claus Hanusch, B Felder, G. von Minckwitz, D. M. Zahm, Nicole Burchardi, F Marmé, PA Fasching, C Denkert, S. Loibl, J Huober, Michael Untch, K Rhiem, J-U Blohmer
Publikováno v:
Cancer Research. 79:PD2-07
Background: The GeparNuevo trial showed a numerical increase in the pCR rate to 53% vs 44%; p=0.281 compared to placebo in TNBC with the addition of the anti-PD-L1 antibody durvalumab to a neoadjuvant anthracycline-taxane containing chemotherapy (Loi
Autor:
Lisa H. Lam, Michael DiGiovanna, Melanie Smitt, C-S Huang, S. Loibl, Andrés Redondo, E Rota Caremoli, PA Fasching, Claudia Arce-Salinas, G. von Minckwitz, Charles E. Geyer, Pia Wuelfing, Eleftherios P. Mamounas, Irene Wapnir, Alison Conlin, William Jacot, Haiyan Wu, Andreas Schneeweiss, P Rastogi, Mano, J.P. Crown, Stina M. Singel, Holger Fischer, Michael Untch, C. Jackisch, D. Tesarowski, Norman Wolmark, Hannah Douthwaite, Zhimin Shao
Publikováno v:
Cancer Research. 79:GS1-10
Background: Patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant chemotherapy plus HER2-targeted therapy have a high risk of recurrence and death. The current standard of care is continuation of the sam
Autor:
Christian Fesl, Y Devyatko, Sean Ferree, Martin Filipits, Christian F. Singer, Marija Balic, Florian Fitzal, M. Gnant, G. von Minckwitz, Zsuzsanna Bago-Horvath, L Soelkner, B Gray, Günther G. Steger, Richard Greil
Publikováno v:
Cancer Research. 79:P1-17
Background: Therapeutic recommendations for adjuvant treatment of hormone-receptor positive breast cancer patients depend on the individual recurrence risk. A number of genomic assays introduced to achieve this goal, but it's still questioned if they